`Grunenthal GmbH v. Antecip Bioventures II LLC
`PGR2018-00001
`
`Page 1
`
`
`
`
`
`
`
`
`
`1998-1999
`
`
`
`•
`
`
`Glaxo Wellcome, Inc., Research Triangle Park, NC
`US Site Director, R&D Worldwide Project Planning
`• Managed US Planning staff, numbering approximately 30, and responsible for infrastructure
`support for department of ~50, including cost center manager. Member of WWPP senior
`management team.
`Instrumental in fostering an increased focus on formal project management. Participated in
`introducing a course on the tools and techniques of project management.
`
`
`
`
`
`
`
`1997-1998
`
`
`
`Glaxo Wellcome, Inc., Research Triangle Park, NC
`Associate Director, R&D Worldwide Project Planning
`• Led a group of project planners responsible for Oncology and Anesthesiology portfolio.
`International Product Development Team leader for 506U78; a potential treatment for leukemias
`•
`and lymphomas.
`
`
`1995-1997
`
`
`
`Glaxo Wellcome, Inc., Research Triangle Park, NC
`International Director, Oncology, Anti-emesis & Anesthesiology, Worldwide Clinical
`Pharmacology
`• Led an international group with responsibility for first time in man studies of Glaxo Wellcome
`compounds in the Oncology, Emesis and Anesthesiology areas. Member of Worldwide Clinical
`Pharmacology senior management team.
`• Appointed International Product Development Team Leader for 506U78.
`• Worked with external investigators in the US, Holland, and the UK to conduct Glaxo Wellcome
`sponsored Phase I clinical trials.
`
`
`
`Burroughs Wellcome Co., Research Triangle Park, NC
`Group Leader, Division of Pharmacokinetics and Drug Metabolism
`• Led a group of pharmacokineticists and bioanalysts working on a broad range of Wellcome
`projects.
`• Served as pharmacokineticist on project teams for a wide variety of drug development programs
`including involvement in NDA submissions for LAMICTAL®, NUROMAX®, MIVACRON®,
`and NAVELBINE®. Participated in FDA Advisory Committee meetings for LAMICTAL,
`MIVACRON, and NAVELBINE.
`• Chaired US Bioanalytical Methods Review Committee and participated as a member of a global
`bioanalytical steering group.
`
`
`
`1987-1995
`
`
`Burroughs Wellcome Co., Research Triangle Park, NC
`Senior Pharmacokineticist, Division of Medicinal Biochemistry
`• Functional line representative for pharmacokinetics on a broad range of Wellcome projects in
`the therapeutic areas of oncology, neurology, cardiovascular and anesthesiology.
`
`
`
`
`
`1983-1987
`
`
`University of North Carolina, School of Pharmacy, Chapel Hill, NC
`Assistant Professor, Division of Pharmaceutics
`• Taught undergraduate courses in Nonprescription Drugs and Pharmacokinetics, and graduate-
`level course in Clinical Pharmacokinetics and Advanced Pharmacokinetics.
`• Faculty Advisor for two M.S. students and one Ph.D. student.
`
`
`
`1977-1983
`
`William Wargin, Ph.D. Nuventra, Inc.
`
`
`
`
`
`
`December 2016
`
`
`Page 2
`
`
`
`
`
`
`
`1967-1972
`
`EDUCATION
`
`1972-1978
`
`University of Minnesota, College of Pharmacy, Minneapolis, MN
`Graduate work leading to a Ph.D. in Pharmaceutics with a specialty in Pharmacokinetics.
`- Advisor: Dr. Ronald Sawchuk
`
`
`University of Minnesota, College of Pharmacy, Minneapolis, MN
`Undergraduate work in Pharmacy leading to a B.S. in Pharmacy with Distinction.
`
`
`ADDITIONAL EXPERIENCE AND TRAINING
`
`Participant in Burroughs Wellcome Management Institute at UNC Kenan-Flagler School of
`Business
`
`
`
`
`
`
`
`
`
`Spring 1995
`
`Member of CANDA Guidance Manual Joint Task Force between
`FDA and PhRMA
`
`
`
`
`
`
`
`
`Faculty Member and Adjunct Associate Professor, Curriculum for Toxicology,
`University of North Carolina at Chapel Hill
`
`
`
`
`1980-1995
`Instructor in Biotransformation of Xenobiotics Course, and served on a number of dissertation
`committees.
`
`Consultant to Food and Drug Administration, Biopharmaceutics Branch
`Reviewed ANDA submissions for generic drugs as an expert reviewer.
`
`Member of Drug Information Association and Project Management Institute
`
`
`
`1990-1992
`
`1980-1983
`
`William Wargin, Ph.D. Nuventra, Inc.
`
`
`
`
`
`
`December 2016
`
`
`Page 3
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
